Experimental and epidemiological data have suggested that vitamin E supplementation may prevent cancer and cardiovascular events, according to background information in the article. Clinical trials have generally failed to confirm benefits, possibly due to their relatively short duration.
Eva Lonn, M.D., of the Population Health Research Institute and McMaster University, Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada, and colleagues conducted a study to evaluate whether long-term supplementation with vitamin E decreases the risk of cancer, cancer death, and major cardiovascular events. The randomized, double-blind, placebo-controlled trial (Heart Outcomes Prevention Evaluation [HOPE]) was initially conducted between December 21, 1993, and April 15, 1999, and included patients at least 55 years old with vascular disease or diabetes mellitus. This trial was extended (HOPEThe Ongoing Outcomes [HOPE-TOO]) to between April 16, 1999, and May 26, 2003.
Of the initial 267 HOPE centers that had enrolled 9,541 patients, 174 centers participated in the HOPE-TOO trial. Of 7,030 patients enrolled at these centers, 916 were deceased at the beginning of the extension, 1,382 refused participation, 3,994 continued to take the study intervention, and 738 agreed to follow-up. Median duration of follow-up was 7.0 years. Patients received a daily dose of natural source vitamin E (400 IU) or matching placebo.
The researchers found: "In the HOPE and HOPE-TOO trials, the daily administration of 400 IU of natural source vitamin E for a median of 7.0 years had no clear impact on fatal and nonfatal cancers, major cardiovascular events, or deaths. We observed an increase in the risk of heart failu
Contact: Veronica McGuire
JAMA and Archives Journals